Gemcitabine and Cisplatin in Refractory Malignant Lymphoma

Publisher： Karger

E-ISSN： 1423-0232|66|3|197-200

ISSN： 0030-2414

Source： Oncology, Vol.66, Iss.3, 2004-06, pp. : 197-200

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine Monotherapy as Second-Line Treatment in Cisplatin-Refractory Transitional Cell Carcinoma – Prognostic Factors for Response and Improvement of Quality of Life

By  

Oncology Research and Treatment, Vol. 25, Iss. 1, 2002-03 ,pp. : 47-52

Karger

Access to resources Recommend Favorite

Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐GEM‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 3, 2015-03 ,pp. : 219-226

John Wiley & Sons Inc

Access to resources Recommend Favorite

Classification of Malignant Lymphoma

By  

Oncology Research and Treatment, Vol. 25, Iss. 6, 2003-01 ,pp. : 563-570

Karger

Access to resources Recommend Favorite

Cutaneous Malignant Lymphoma in an Infant

By  

THE JOURNAL OF DERMATOLOGY, Vol. 17, Iss. 12, 1990-12 ,pp. : 755-759

John Wiley & Sons Inc

Access to resources Recommend Favorite

HIV-Associated Malignant Lymphoma

By  

Oncology Research and Treatment, Vol. 40, Iss. 3, 2017-02 ,pp. : 82-87

Karger

Access to resources Recommend Favorite